ID   Ma-Mel-100b
AC   CVCL_A1DY
DR   Cosmic; 2757117
DR   GEO; GSM1467850
DR   Wikidata; Q102114492
RX   PubMed=25294904;
CC   Sequence variation: Gene deletion; HGNC; HGNC:914; B2M; Zygosity=Heterozygous (PubMed=25294904).
CC   Sequence variation: Mutation; HGNC; HGNC:914; B2M; Simple; p.Leu60_Glu64delinsGln (c.179_190del); Zygosity=Heterozygous (PubMed=25294904).
CC   Omics: SNP array analysis.
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000029.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_A124 ! Ma-Mel-100a
SX   Male
AG   77Y
CA   Cancer cell line
DT   Created: 29-10-20; Last updated: 19-12-24; Version: 7
//
RX   PubMed=25294904; DOI=10.1158/1078-0432.CCR-14-0567; PMCID=PMC8728890;
RA   Sucker A., Zhao F., Real B., Heeke C., Bielefeld N., Massen S.,
RA   Horn S., Moll I., Maltaner R., Horn P.A., Schilling B., Sabbatino F.,
RA   Lennerz V., Kloor M., Ferrone S., Schadendorf D., Falk C.S.,
RA   Griewank K.G., Paschen A.;
RT   "Genetic evolution of T-cell resistance in the course of melanoma
RT   progression.";
RL   Clin. Cancer Res. 20:6593-6604(2014).
//